Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 13,000 | |||
2 mg | 在庫あり | ¥ 18,000 | |||
5 mg | 在庫あり | ¥ 27,500 | |||
10 mg | 在庫あり | ¥ 45,500 | |||
50 mg | 在庫あり | ¥ 105,500 | |||
100 mg | 在庫あり | ¥ 154,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 38,500 |
説明 | Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM). |
ターゲット&IC50 | Aurora A:171 nM (ki), Aurora B:436.76 nM (ki), PLK4 (G95L):68.57 nM (ki), PLK4:0.16 nM (ki) |
In vitro | Centrinone (LCR-263) treatment causes centrosome depletion in human and other vertebrate cells and it treatment reduces centriole number in multiciliated Xenopus epithelial cells, which indicates that Plk4 also controls centriole amplification in differentiated cells. Centrinone (LCR-263) treatment of HeLa human cervical carcinoma cells leads to a progressive reduction in foci containing centriolar and pericentriolar material markers at each round of cell division, until most cells lack centrioles and centrosomes. Centrosome loss irreversibly arrests normal cells in a senescence-like G1 state by a p53-dependent mechanism that is independent of DNA damage, stress, Hippo signaling, extends mitotic duration, or segregation errors[1]. |
別名 | LCR-263 |
分子量 | 633.65 |
分子式 | C26H25F2N7O6S2 |
CAS No. | 1798871-30-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31 mg/mL (48.92 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Centrinone 1798871-30-3 Cell Cycle/Checkpoint Chromatin/Epigenetic PLK Aurora Kinase LCR 263 Polo-like Kinase (PLK) LCR263 Inhibitor inhibit LCR-263 inhibitor